{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05568225",
            "orgStudyIdInfo": {
                "id": "4202-ONC-203"
            },
            "organization": {
                "fullName": "Novo Nordisk A/S",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)",
            "officialTitle": "A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-of-etavopivat-for-the-treatment-of-anemia-in-patients-with-myelodysplastic-syndromes-mds"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-15",
            "studyFirstSubmitQcDate": "2022-09-30",
            "studyFirstPostDateStruct": {
                "date": "2022-10-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Forma Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS."
        },
        "conditionsModule": {
            "conditions": [
                "Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R"
            ],
            "keywords": [
                "Anemia",
                "Myelodysplastic Syndromes",
                "MDS",
                "Pyruvate Kinase",
                "Activator",
                "Transfusion dependent",
                "FT-4202",
                "Etavopivat",
                "IPSS-R very low risk",
                "IPSS-R low risk",
                "IPSS-R intermediate risk",
                "ESA refractory",
                "ESA intolerant",
                "Luspatercept refractory",
                "Luspatercept intolerant"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 45,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Etavopivat 400 mg QD daily",
                    "type": "EXPERIMENTAL",
                    "description": "Non-transfusion dependent (NTD), Low transfusion burden (LTB) , and High transfusion burden (HTB) patients",
                    "interventionNames": [
                        "Drug: Etavopivat"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Etavopivat",
                    "description": "400 mg once daily",
                    "armGroupLabels": [
                        "Etavopivat 400 mg QD daily"
                    ],
                    "otherNames": [
                        "FT-4202"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "The hematologic improvement based on an erythroid response (HI -E) \u2265 8 weeks duration in patients with MDS after 16 weeks of etavopivat treatment",
                    "description": "Measure in number of patient incidence\n\nThis endpoint will be based on the combined incidence of:\n\n* Non-transfusion dependent (NTD) patients: \u2265 1.5 g/dL increase in hemoglobin (Hb) from baseline maintained \u2265 8 consecutive weeks\n* Low transfusion burden (LTB) patients: absence of any transfusion for \u2265 8 consecutive weeks\n* High transfusion burden (HTB) patients: reduction by \u2265 50% of red blood cell (RBC) units for \u2265 8 consecutive weeks",
                    "timeFrame": "16 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "The HI-E \u2265 8 weeks duration in this population of patients after 24 and 48 weeks of etavopivat treatment",
                    "description": "Measure in number of patient incidence\n\nThis endpoint will be based on the combined incidence of:\n\n* Non-transfusion dependent (NTD) patients: \u2265 1.5 g/dL increase in hemoglobin (Hb) from baseline maintained \u2265 8 consecutive weeks\n* Low transfusion burden (LTB) patients: absence of any transfusion for \u2265 8 consecutive weeks\n* High transfusion burden (HTB) patients: reduction by \u2265 50% of red blood cell (RBC) units for \u2265 8 consecutive weeks",
                    "timeFrame": "24 and 48 weeks"
                },
                {
                    "measure": "The HI-E \u2265 16 weeks duration in this population of patients after 24 and 48 weeks of etavopivat treatment",
                    "description": "Measure in number of patient incidence\n\nThis endpoint will be based on the combined incidence of:\n\n* Non-transfusion dependent (NTD) patients: \u2265 1.5 g/dL increase in hemoglobin (Hb) from baseline maintained \u2265 16 consecutive weeks\n* Low transfusion burden (LTB) patients: absence of any transfusion for \u2265 16 consecutive weeks\n* High transfusion burden (HTB) patients: reduction by \u2265 50% of red blood cell (RBC) units for \u2265 16 consecutive weeks",
                    "timeFrame": "24 and 48 weeks"
                },
                {
                    "measure": "Incidence of AEs, serious adverse events (SAEs), and AEs related to etavopivat",
                    "description": "Measure in number of patient incidences",
                    "timeFrame": "4(first 6 participants), 16, 24, and 48 weeks"
                },
                {
                    "measure": "Number of premature discontinuations, dose interruptions, and dose reductions",
                    "description": "Measure in number of patient incidences",
                    "timeFrame": "4(first 6 participants), 16, 24, and 48 weeks"
                },
                {
                    "measure": "Overall response rate for MDS",
                    "description": "Measure in number of patient incidence, per Chelson, 2006 International Working Group \\[IWG\\] Criteria",
                    "timeFrame": "16, 24, and 48 weeks."
                },
                {
                    "measure": "Duration of response",
                    "description": "Measure in number of days, per 2006 IWG Criteria",
                    "timeFrame": "16, 24, and 48 weeks."
                },
                {
                    "measure": "Percentage of participants who achieved RBC transfusion independence in participants with LTB or HTB at study entry",
                    "description": "Measure in percentage",
                    "timeFrame": "16, 24, and 48 weeks."
                },
                {
                    "measure": "Change from baseline in RBC units transfused in patients with NTD, LTB or HTB at study entry",
                    "description": "Measure in RBC units",
                    "timeFrame": "16, 24, and 48 weeks."
                },
                {
                    "measure": "Participants who achieved a hematologic improvement in neutrophil",
                    "description": "Measure in number of patient incidence",
                    "timeFrame": "16, 24, and 48 weeks."
                },
                {
                    "measure": "Participants who achieved a hematologic improvement in platelet response",
                    "description": "Measure in number of patient incidence",
                    "timeFrame": "16, 24, and 48 weeks."
                },
                {
                    "measure": "Change from baseline in mean serum ferritin",
                    "description": "Measure in ng/mL",
                    "timeFrame": "16, 24, and 48 weeks."
                },
                {
                    "measure": "Change from baseline in mean daily dose of iron chelation therapy",
                    "description": "Measure in dose unit",
                    "timeFrame": "16, 24, and 48 weeks."
                },
                {
                    "measure": "Overall survival",
                    "description": "Measure in number of patient incidence",
                    "timeFrame": "16, 24, and 48 weeks."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "INCLUSION CRITERIA:\n\n1. Patient has provided documented informed consent; the informed consent form (ICF) must be reviewed and signed by each patient prior to any study-related assessments/procedures being conducted.\n2. Age \u2265 18 years at time of first dose.\n3. Patients, if female and of childbearing potential, must agree to use acceptable methods of contraception and agree not to donate ova from study start to 90 days after the last dose of study drug, and who if male are willing to use acceptable methods of contraception and agree not to donate sperm, from study start to 90 days after the last dose of study drug.\n4. Documented diagnosis of idiopathic/de novo MDS according to World Health Organization (WHO) classification that meets the IPSS-R classification of very low, low, or intermediate risk disease, and:\n\n   * \\< 5% blasts in bone marrow based on local pathology review\n   * \\< Intermediate risk cytogenetic abnormalities per IPSS-R\n5. Anemia defined as:\n\n   * Non-transfusion dependent (NTD): Subjects with mean Hb concentration \\< 10.0 g/dL of 2 measurements (1 performed within 3 days prior to Day 1 and the other performed 7 to 28 days prior to Day 1, not influenced by RBC transfusion within 7 days of measurement) and \\< 3 RBC transfusions for anemia in the prior 16 weeks before Day 1 of etavopivat dosing\n\n   OR\n   * Transfusion dependent (TD): Subjects having received \u2265 3 units of RBCs for the treatment of anemia within 16 weeks prior to Day 1\n6. Serum erythropoietin level \\> 200 U/L, OR, if \u2264 200 U/L, subject is non-responsive, refractory, or intolerant to erythropoiesis-stimulating agents, or erythropoiesis-stimulating agents are contraindicated or unavailable.\n7. ECOG performance status of \u2264 2\n8. Subject is non-responsive, refractory, or intolerant to luspatercept, or luspatercept is contraindicated or not indicated.\n9. No alternative treatment options are available and/or appropriate for the subject, at the discretion of the investigator.\n10. Patient is willing and able to adhere to the study visit schedule and other protocol requirements\n\nEXCLUSION CRITERIA:\n\n\\[MDS History\\]\n\n1. MDS associated with del 5q cytogenetic abnormality and known TP53 abnormality\n2. Therapy-associated MDS (eg. t-MDS) that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases\n3. Known history of acute myeloid leukemia (AML)\n\n   \\[Medical Conditions\\]\n4. Female who is breast feeding or pregnant\n5. Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding\n6. Absolute neutrophil count \\< 500/\u00b5L (0.5 x 10\\^9/L)\n7. Platelet count \\< 50,000/\u00b5L (50 x 10\\^9/L) without transfusion support within 2 weeks\n8. Hepatic dysfunction characterized by:\n\n   * Alanine aminotransferase (ALT) \\> 5.0 \u00d7 upper limit of normal (ULN)\n   * Total bilirubin \\> 3.0 \u00d7 ULN\n   * History of cirrhosis\n9. Severe renal dysfunction (estimated glomerular filtration rate at the Screening visit; calculated by the local laboratory \\< 30 mL/min/1.73 m\\^2 ) or on chronic dialysis.\n10. Patients with clinically significant and active bacterial, fungal, parasitic, or viral infection.\n\n    * Patients with acute bacterial, fungal, parasitic, or viral infection requiring systemic therapy should delay Screening/ enrollment until active therapy has been completed.\n    * Patients with acute viral infections without available therapies (eg, coronavirus disease 2019 \\[COVID-19\\]) should delay Screening/ enrollment until the acute infection has resolved.\n\n    Note: Infection prophylaxis is allowed.\n11. Known human immunodeficiency virus (HIV) positivity\n12. Active infection with hepatitis B virus (hepatitis B surface antigen \\[HepBsAg\\] and hepatitis B core antibody \\[HepBcAb\\] positive)\n13. Active hepatitis C infection\n14. History of malignancy, other than MDS, within the past 2 years prior to treatment Day 1 requiring systemic chemotherapy and/or radiation.\n\n    * Patients with malignancy considered surgically cured are eligible (eg, non-melanoma skin cancer, carcinoma in situ of the cervix, or carcinoma in situ of the breast)\n    * Patients with incidental histologic findings of prostate cancer (T1a or T1b) are eligible\n15. History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:\n\n    * Unstable angina pectoris or myocardial infarction or elective coronary intervention\n    * Heart disease, heart failure as classified by the New York Heart Association classification 3 or higher, or significant arrhythmia requiring treatment,\n    * Pulmonary fibrosis or pulmonary hypertension which are clinically significant ie, \u2265 Grade 3 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (or higher)\n16. Uncontrolled hypertension, defined as repeated elevation of diastolic blood pressure \u2265 100 mmHg despite adequate treatment\n17. Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable).\n\n    \\[Prior/Concomitant Therapy\\]\n18. Prior treatment with azacitidine (injectable or oral) or decitabine\n19. Use of erythropoietin, other hematopoietic growth factor treatment or lenalidomide within 30 days of starting study treatment or anticipated need for such agents during the study.\n20. Prior use of luspatercept:\n\n    * NTD patients must not have received luspatercept within 30 days prior to Day 1 treatment\n    * TD patients must not have received luspatercept within 16 weeks prior to Day 1 treatment\n21. Receiving or use of concomitant medications that are strong inducers of cytochrome P450 (CYP)3A4/5 (see Appendix F) within 2 weeks of starting study treatment or anticipated need for such agents during the study.\n22. Prior allogeneic or autologous stem cell transplant\n23. Initiation of a new chelation therapy within 3 months before the first dose of study treatment.\n\n    \\[Prior/Concurrent Clinical Study Experience\\]\n24. Participated in another clinical trial of an investigational agent (or medical device) within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently participating in another trial of an investigational agent (or medical device).\n\n    \\[Other Exclusions\\]\n25. Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, confound study interpretation, interfere with compliance, or preclude informed consent.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Novo Nordisk",
                    "role": "CONTACT",
                    "phone": "(+1) 866-867-7178",
                    "email": "clinicaltrials@novonordisk.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Transparency (dept. 2834), MD",
                    "affiliation": "Novo Nordisk A/S",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Miami Hospital and Clinics",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Ocala Oncology",
                    "status": "RECRUITING",
                    "city": "Ocala",
                    "state": "Florida",
                    "zip": "34474",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.1872,
                        "lon": -82.14009
                    }
                },
                {
                    "facility": "University of Maryland Greenebaum Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21201",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Maimonides Medical Center",
                    "status": "RECRUITING",
                    "city": "Brooklyn",
                    "state": "New York",
                    "zip": "11219",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.6501,
                        "lon": -73.94958
                    }
                },
                {
                    "facility": "NYU Langone Health",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Columbia University Irving Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Baptist Clinical Research Institute",
                    "status": "RECRUITING",
                    "city": "Memphis",
                    "state": "Tennessee",
                    "zip": "38120",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.14953,
                        "lon": -90.04898
                    }
                },
                {
                    "facility": "University of British Columbia - St. Paul's Hospital",
                    "status": "RECRUITING",
                    "city": "Vancouver",
                    "state": "British Columbia",
                    "zip": "V6Z 2K5",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 49.24966,
                        "lon": -123.11934
                    }
                },
                {
                    "facility": "Nice University Hospital - H\u00f4pital de l'Archet",
                    "status": "RECRUITING",
                    "city": "Route De Saint-Antoine",
                    "state": "Nice",
                    "zip": "06200",
                    "country": "France"
                },
                {
                    "facility": "H\u00f4pital Avicenne",
                    "status": "RECRUITING",
                    "city": "Bobigny",
                    "zip": "93000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.9,
                        "lon": 2.45
                    }
                },
                {
                    "facility": "CHU de Nantes - H\u00f4tel Dieu",
                    "status": "RECRUITING",
                    "city": "Nantes",
                    "zip": "44000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.21725,
                        "lon": -1.55336
                    }
                },
                {
                    "facility": "Hopital Saint Louis",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Universitoetsklinikum Heidelberg",
                    "status": "RECRUITING",
                    "city": "Heidelberg",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 49.40768,
                        "lon": 8.69079
                    }
                },
                {
                    "facility": "Universitaetsklinikum Muenster",
                    "status": "RECRUITING",
                    "city": "M\u00fcnster",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.96236,
                        "lon": 7.62571
                    }
                },
                {
                    "facility": "Universitoetsklinikum Halle (Saale)",
                    "status": "RECRUITING",
                    "city": "M\u00fcnster",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.96236,
                        "lon": 7.62571
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011289",
                    "term": "Preleukemia"
                },
                {
                    "id": "D000000740",
                    "term": "Anemia"
                },
                {
                    "id": "D000009190",
                    "term": "Myelodysplastic Syndromes"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000011230",
                    "term": "Precancerous Conditions"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M4070",
                    "name": "Anemia",
                    "asFound": "Anemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14164",
                    "name": "Preleukemia",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12145",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14111",
                    "name": "Precancerous Conditions",
                    "relevance": "LOW"
                },
                {
                    "id": "T3993",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M352828",
                    "name": "Luspatercept",
                    "relevance": "LOW"
                },
                {
                    "id": "T424",
                    "name": "Pyruvate",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Ot",
                    "name": "Other Dietary Supplements"
                }
            ]
        }
    },
    "hasResults": false
}